What's new?

Sofinnova Partners Announces Sale of Corvidia Therapeutics to Novo Nordisk

Novo Nordisk acquires Corvidia for $2.1B with an upfront payment of $725M in cash   Sofinnova Partners co-founded Corvidia as its sole seed financial investor in 2015 with serial entrepreneur Michael Davidson   PARIS, France – June 11, 2020 - Sofinnova Partners, a leading European life sciences venture capital firm...

DNA Script Expands Series B to $89M

Casdin Capital leads the $50M extension; funding will support commercial launch of SYNTAX™ the world’s first enzymatic DNA printer. July 29, 2020 03:00 AM Eastern Daylight Time PARIS & SOUTH SAN FRANCISCO--(BUSINESS WIRE)--DNA Script today announced a $50 million extension to its Series B financing, bringing the to...

Enthera Pharmaceuticals raises €28 million in Series A financing to advance restorative therapy for type 1 diabetes and inflammatory bowel disease

Financing co-led by seed investor Sofinnova Partners and incoming investor AbbVie, with additional investment from JDRF T1D Fund and several Italian investors   Largest international VC-backed Series A financing round for biotech in Italy to date and first ever venture investment in an Italian company by AbbVie   F...

Inotrem Receives Clearance From French, Belgian And US Authorities to Launch a Phase II Clinical Trial Aimed at Assessing Nangibotide in Mechanically Ventilated Patients With COVID-19

Inotrem’s clinical study on Covid-19 was selected by the French government to be part of its €78 M action plan aimed at reinforcing the countries’ research capabilities for therapeutic solutions.   Pre-clinical studies have demonstrated nangibotide’s capacity to restore an appropriate immune response by targeting t...

ProQR Strengthens Scientific Advisory Board with Leaders in Inherited Retinal Disease and RNA Therapy

LEIDEN, Netherlands & CAMBRIDGE, Mass., July 21, 2020 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA therapies for severe genetic rare diseases, today announced the strengthening of the Company’s Scientific Advisory Board (...

CorWave Awarded €2.5M From the European Commission Through the EIC Accelerator Program

Clichy, France, July 21st, 2020 – CorWave is one of the 44 companies selected among 1,800+ applicants by the European public program EIC Accelerator. CorWave will receive a €2.5 million grant from the European Innovation Council (EIC) to develop its innovative Left Ventricular Assist Device (LVAD). 

Shockwave Appoints Maria Sainz to Board of Directors

SANTA CLARA, Calif., July 20, 2020 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development of Intravascular Lithotripsy (IVL) to treat complex calcified cardiovascular disease, announced today that Maria Sainz has joined its Board of Directors and will serve on Shockwave’s Compensat...

Verona Pharma Raises $200 Million in Oversubscribed Private Placement and Subscription

Funding to support Phase 3 ENHANCE clinical program in COPD   July 17, 2020 02:00 ET | Source: Verona Pharma plc   THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF THE MARKET ABUSE REGULATION (EU) NO. 596/2014 (“MAR”). UPON PUBLICATION OF THIS ANNOUNCEMENT THIS INFORMATION IS NOW CONSI...

Comet Bio Wins “Start-Up of the Year” NutraIngredients Award for 2020

SCHAUMBURG, Ill., July 14, 2020 /PRNewswire/ – Comet Bio, a manufacturer of healthy, sustainable, and award-winning ingredients, announced today it has been named the winner of this year’s NutraIngredients USA Start-Up of the Year award.  This award recognizes the company’s unique line of innovative ingredients and...

Venus Medtech to Partner with Pi-Cardia to Bring its Leaflex(TM) Aortic Valve Technology to China

Jul 14, 2020, 06:11 ET HANGZHOU, China and REHOVOT, Israel, July 14, 2020 /PRNewswire/ -- Venus Medtech (Hangzhou) Inc. (stock code: 2500.HK), the leading transcatheter heart valve medical device player in China, and Pi-Cardia Ltd., a global leader in the development of non-implant catheter-based solutions for trea...

Inventiva announces the pricing of its initial public offering on the Nasdaq Global Market

Daix (France), July 10, 2020 – INVENTIVA S.A. (Euronext Paris: IVA) (“Inventiva” or the “Company”), a clinical- stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (“NASH”), mucopolysaccharidoses (“MPS”) and other diseases wi...

1 2 3 4 5